サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1558400

胃腸薬の世界市場規模・予測、世界・地域別シェア、動向、成長機会分析：薬剤クラス別、用途別、投与経路別、流通チャネル別、地域別

Gastrointestinal Drugs Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class, Application, Route Of Administration, Distribution Channel, and Geography
出版日: | 発行: The Insight Partners | ページ情報: 英文 211 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=150.96円
胃腸薬の世界市場規模・予測、世界・地域別シェア、動向、成長機会分析：薬剤クラス別、用途別、投与経路別、流通チャネル別、地域別
出版日: 2024年08月30日
発行: The Insight Partners
ページ情報: 英文 211 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

弊社の最新調査レポート「胃腸薬市場の2031年までの予測：薬剤クラス別、用途別、投与経路別、流通チャネル別の世界分析」によると、胃腸薬市場は2023年の597億1,368万米ドルから成長し、2031年には1,063億481万米ドルに達すると予測され、2023年～2031年にCAGR7.3%を記録すると予測されています。胃腸薬市場の成長は、胃腸疾患の有病率の増加と胃腸疾患に対する生物製剤の開発の増加に起因しています。

胃腸薬は、食道、胃、腸および関連臓器を含む消化器系に影響を及ぼす疾患や状態を治療するために特別に設計された薬剤です。これらの薬剤は、症状の管理、疼痛の緩和、基礎疾患の治療に役立ちます。

2023年の世界の胃腸薬市場は、北米が大きなシェアを占めています。北米の胃腸薬市場は米国、カナダ、メキシコに区分されます。ライフスタイルの変化による消化器疾患の発生率の増加、消化器疾患の予防と治療に対する政府の支援、整備された医療インフラの存在、成長する製薬業界、償還範囲、業界大手などが北米の市場成長を促進する顕著な要因です。

北米では、米国が胃腸薬の最大市場です。米国では、消化器疾患の有病率の増加が胃腸薬の需要に直接貢献しています。クローン病と潰瘍性大腸炎は、最も一般的な炎症性腸疾患（IBD）の2つです。米国クローン病・大腸炎財団（CCFA）の報告書「Facts about IBD」によると、米国では年間約7万人が新たにIBDと診断されています。IBDの全有病率は2011年～2020年に大幅に増加しました。100人に1人近くがIBDであり、約240万人のアメリカ人が何らかの形でIBDに罹患していると推定されています。さらに、消化器疾患に関連する研究開発のための資金が増加していることから、新規治療薬の開発に焦点が当てられるようになると予想されます。2022年に発表された「子宮内膜症は過小評価されている」と題された調査によると、クローン病研究には9,000万米ドル（患者1人当たり130.07米ドル）の資金が提供されています。

米国食品医薬品局（FDA）の承認が市場の成長を支えていると思われます。例えば、2020年5月、米国FDAはQinlock（ripretinib）錠剤を進行性消化管間質腫瘍（GIST）の4次治療薬として承認しました。2024年5月には、Strides PharmaがSucralfate Oral Suspension, 1gm/10mLのジェネリック医薬品について、米国FDAから胃潰瘍、胃食道逆流症（GERD）、胃炎などの消化器疾患の治療薬として承認を取得し、ストレス性潰瘍を予防しています。

したがって、この市場の成長は、胃腸疾患の有病率の増加、市場企業による開発、米国における主要市場企業の存在によって促進されています。

胃腸薬における戦略的取り組みが今後の市場機会をもたらす

胃腸薬市場で事業を展開する企業は、製品承認、提携、資金調達、契約、新製品発売などの戦略的開拓に絶えず注力しており、売上の向上、地理的リーチの拡大、既存顧客ベースよりも多くの顧客に対応するための能力向上に貢献しています。胃腸薬市場で事業を展開する主要企業の戦略的イニシアチブを以下にいくつか紹介します。

2023年9月、ビバンテ・ヘルスはデジタル消化器健康プラットフォームを推進するため、新たな投資家であるメルカート・パートナーズが主導するシリーズB資金調達ラウンドで3,100万米ドルを調達しました。この新たな資金調達は主に、適切なタイミングで適切なケアを提供する同プラットフォームのユニークな能力を際立たせる最新のGIThriveプラットフォームの機能強化によるものです。シリーズB資本は、消化器疾患の発症と進行を予測し、完全なバーチャルケアを提供するために設計された継続的な技術的進歩を提供します。

2024年5月、Strides Pharma Global Pte.Ltd.は、米国FDAからSucralfate Oral Suspension, 1gm/10mLのジェネリック医薬品の販売承認を取得しました。同剤は胃潰瘍、GERD、胃炎などの消化器疾患の治療やストレス性潰瘍の予防に使用されます。

2023年5月、アッヴィはRINVOQ（ウパダシチニブ）について、1種類以上のTNF阻害剤で効果不十分または不耐容の軽度から重度の活動性クローン病の成人患者を対象とした治療薬として米国FDAの承認を取得しました。RINVOQのFDA承認は、リウマチ科、皮膚科、消化器科にまたがる7番目の承認であり、潰瘍性大腸炎とクローン病の両方に適応があります。

したがって、消化器系疾患の治療薬の開発に注力するさまざまな企業による戦略的イニシアチブは、今後数年間、胃腸薬市場に成長機会をもたらす可能性が高いと思われます。

胃腸薬市場：競合情勢と主な発展

サノフィSA、GSK Plc、ジョンソン・エンド・ジョンソン、Bausch Health Companies Inc、AstraZeneca Plc、武田薬品工業、AbbVie Inc、Bayer AG、Celltrion Inc、Pfizer Incは、胃腸薬市場で事業を展開する主要企業です。

米国食品医薬品局、国際胃腸障害財団、米国消化器病学会、国際基礎臨床薬理学連合（IUPHAR）などは、胃腸薬市場レポート作成時に参照した一次情報および二次情報です。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

  • 主要な洞察

第3章 調査手法

  • 2次調査
  • 1次調査
    • 仮説の策定
    • マクロ経済要因分析
    • 基礎数値の作成
    • データの三角測量
    • 国レベルのデータ

第4章 胃腸薬の市場情勢

  • PEST分析

第5章 胃腸薬市場-主要市場力学

  • 胃腸薬市場- 主な市場力学
  • 市場促進要因
    • 消化器疾患の増加
    • 生物学的製剤の開発増加
  • 市場抑制要因
    • 生物学的製剤の高コスト
    • 重症潰瘍性大腸炎またはクローン病に対する生物学的製剤の平均コスト
  • 市場機会
    • 企業による戦略的取り組み
  • 今後の動向
    • 新薬開発のための研究投資と人工知能ベースの技術の増加
  • 促進要因と抑制要因の影響

第6章 胃腸薬市場-世界市場分析

  • 胃腸薬市場の売上高（2021年～2031年）
  • 胃腸薬市場の予測分析

第7章 胃腸薬市場分析-薬剤クラス別

  • 生物学的製剤
  • 止瀉薬と下剤
  • 酸中和剤
  • 抗炎症薬
  • 制吐剤と吐き気止め
  • その他

第8章 胃腸薬市場分析-用途別

  • 過敏性腸症候群
  • 炎症性潰瘍性大腸炎
  • クローンズ病
  • 胃腸炎
  • セリアック病
  • その他

第9章 胃腸薬市場分析-投与経路別

  • 経口
  • 非経口

第10章 胃腸薬市場分析-流通チャネル別

  • 院内薬局
  • 小売薬局
  • オンライン薬局

第11章 胃腸薬市場分析 - 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • オーストラリア
    • 韓国
    • その他アジア太平洋
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • アラブ首長国連邦
    • その他中東・アフリカ
  • 中南米
    • ブラジル
    • アルゼンチン
    • その他中南米

第12章 業界情勢

  • 胃腸薬市場における成長戦略
  • 有機的成長戦略
  • 無機的成長戦略

第13章 企業プロファイル

  • Sanofi SA
  • GSK Plc
  • Johnson & Johnson
  • Bausch Health Companies Inc
  • AstraZeneca Plc
  • Takeda Pharmaceutical Co Ltd
  • AbbVie Inc
  • Bayer AG
  • Celltrion Inc
  • Pfizer Inc

第14章 付録

図表

List Of Tables

  • Table 1. Gastrointestinal Drugs Market Segmentation
  • Table 2. North America: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 3. North America: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 4. North America: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 5. North America: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 6. United States: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 7. United States: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 8. United States: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 9. United States: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 10. Canada: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 11. Canada: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 12. Canada: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 13. Canada: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 14. Mexico: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 15. Mexico: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 16. Mexico: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 17. Mexico: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 18. Europe: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 19. Europe: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 20. Europe: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 21. Europe: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 22. Germany: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 23. Germany: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 24. Germany: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 25. Germany: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 26. United Kingdom: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 27. United Kingdom: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 28. United Kingdom: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 29. United Kingdom: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 30. France: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 31. France: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 32. France: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 33. France: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 34. Italy: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 35. Italy: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 36. Italy: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 37. Italy: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 38. Spain: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 39. Spain: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 40. Spain: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 41. Spain: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 42. Rest of Europe: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 43. Rest of Europe: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 44. Rest of Europe: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 45. Rest of Europe: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 46. Asia Pacific: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 47. Asia Pacific: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 48. Asia Pacific: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 49. Asia Pacific: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 50. China: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 51. China: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 52. China: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 53. China: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 54. Japan: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 55. Japan: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 56. Japan: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 57. Japan: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 58. India: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 59. India: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 60. India: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 61. India: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 62. Australia: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 63. Australia: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 64. Australia: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 65. Australia: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 66. South Korea: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 67. South Korea: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 68. South Korea: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 69. South Korea: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 70. Rest of APAC: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 71. Rest of APAC: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 72. Rest of APAC: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 73. Rest of APAC: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 74. Middle East & Africa: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 75. Middle East & Africa: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 76. Middle East & Africa: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 77. Middle East & Africa: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 78. Saudi Arabia: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 79. Saudi Arabia: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 80. Saudi Arabia: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 81. Saudi Arabia: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 82. South Africa: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 83. South Africa: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 84. South Africa: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 85. South Africa: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 86. United Arab Emirates: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 87. United Arab Emirates: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 88. United Arab Emirates: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 89. United Arab Emirates: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 90. Rest of Middle East & Africa: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 91. Rest of Middle East & Africa: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 92. Rest of Middle East & Africa: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 93. Rest of Middle East & Africa: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 94. South & Central America: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 95. South & Central America: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 96. South & Central America: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 97. South & Central America: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 98. Brazil: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 99. Brazil: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 100. Brazil: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 101. Brazil: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 102. Argentina: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 103. Argentina: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 104. Argentina: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 105. Argentina: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 106. Rest of South & Central America: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 107. Rest of South & Central America: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 108. Rest of South & Central America: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 109. Rest of South & Central America: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 110. Recent Organic Growth Strategies in Gastrointestinal Drugs Market
  • Table 111. Recent Inorganic Growth Strategies in the Gastrointestinal Drugs Market
  • Table 112. Glossary of Terms, Gastrointestinal Drugs Market

List Of Figures

  • Figure 1. Gastrointestinal Drugs Market Segmentation, by Geography
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Gastrointestinal Drugs Market Revenue (US$ Million), 2021-2031
  • Figure 5. Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 6. Gastrointestinal Drugs Market Share (%) - by Drug Class (2023 and 2031)
  • Figure 7. Biologics: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Antidiarrheal and Laxatives: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 9. Acid Neutralizers: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Anti-inflammatory Drugs: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. Antiemetic and Antinauseants: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. Others: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Gastrointestinal Drugs Market Share (%) - by Application (2023 and 2031)
  • Figure 14. Irritable Bowel Syndrome: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Inflammatory Ulcerative Colitis: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 16. Crohns Disease: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 17. Gastroenteritis: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. Celiac Disease: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. Others: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 20. Gastrointestinal Drugs Market Share (%) - by Route Of Administration (2023 and 2031)
  • Figure 21. Oral: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. Parenteral: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 23. Gastrointestinal Drugs Market Share (%) - by Distribution Channel (2023 and 2031)
  • Figure 24. Hospital Pharmacies: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 25. Retail Pharmacies: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 26. Online Pharmacies: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 27. North America: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 28. North America: Gastrointestinal Drugs Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 29. United States: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 30. Canada: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 31. Mexico: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 32. Europe: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 33. Europe: Gastrointestinal Drugs Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 34. Germany: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 35. United Kingdom: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 36. France: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 37. Italy: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 38. Spain: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 39. Rest of Europe: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 40. Asia Pacific: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 41. Asia Pacific: Gastrointestinal Drugs Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 42. China: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 43. Japan: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 44. India: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 45. Australia: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 46. South Korea: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 47. Rest of APAC: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 48. Middle East & Africa: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 49. Middle East & Africa: Gastrointestinal Drugs Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 50. Saudi Arabia: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 51. South Africa: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 52. United Arab Emirates: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 53. Rest of Middle East & Africa: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 54. South & Central America: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 55. South & Central America: Gastrointestinal Drugs Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 56. Brazil: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 57. Argentina: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 58. Rest of South & Central America: Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 59. Growth Strategies in Gastrointestinal Drugs Market
目次
Product Code: TIPRE00014758

According to our new research study on "Gastrointestinal Drugs Market Forecast to 2031 -Global Analysis - by Drug Class, Application, Route of Administration, and Distribution Channel," the market is anticipated to grow from US$ 59,713.68 million in 2023 and is projected to reach US$ 106,304.81 million by 2031; it is expected to register a CAGR of 7.3% during 2023-2031. The gastrointestinal drugs market growth is attributed to the increasing prevalence gastrointestinal diseases and increasing developments of biologics for gastrointestinal diseases.

Gastrointestinal drugs are medications specifically designed to treat disorders and conditions affecting the digestive system, which includes the esophagus, stomach, intestines and related organs. These drugs can help manage symptoms, alleviate pain, and treat underlying diseases.

North America accounted for a major share of the global gastrointestinal drugs market in 2023. The North America gastrointestinal drugs market is segmented into the US, Canada, and Mexico. Increasing incidence of gastrointestinal diseases due to change in lifestyle, government support for prevention and treatment of gastrointestinal diseases, presence of well-developed healthcare infrastructure, growing pharmaceutical industry, reimbursement coverage and industry giants are some of the prominent factors propelling the market growth in North America.

In North America, the US is the largest market for gastrointestinal drugs. In the US, the increasing prevalence of gastrointestinal diseases contributes directly to the demand for gastrointestinal drugs. Crohn's disease and ulcerative colitis are two of the most common types of inflammatory bowel diseases (IBD). As per the Crohn's & Colitis Foundation of America (CCFA) report, "Facts about IBD," approximately 70,000 new cases of IBD are diagnosed yearly in the US. The overall prevalence of IBD increased significantly from 2011 to 2020. The study estimates that nearly 1 in 100 Americans have IBD, and ~2.4 million Americans have some form of IBD. Additionally, the rising funding for research and development related to gastrointestinal diseases is expected to increase focus on developing novel treatment medications. Per a study titled "Endometriosis Is Undervalued," published in 2022, Crohn's disease research received US$ 90 million in funding, or US$ 130.07 per patient.

The US Food and Drug Administration (FDA) approvals are likely to support the growth of the market. For instance, in May 2020, the US FDA approved Qinlock (ripretinib) tablets as a fourth-line treatment for advanced gastrointestinal stromal tumors (GIST). In May 2024, Strides Pharma received approval for the generic version of Sucralfate Oral Suspension, 1gm/10 mL, from the US FDA for the treatment of gastrointestinal diseases as well as stomach ulcers, gastroesophageal reflux disease (GERD), and stomach inflammation and prevent stress ulcers.

Therefore, the growth of this market is driven by the growing prevalence of gastrointestinal diseases, developments by the market players, and the presence of major market players in the US.

Strategic Initiatives in Gastrointestinal Drugs to Provide Market Opportunities in Future

Companies operating in the gastrointestinal drugs market constantly focus on strategic developments such as product approvals, collaborations, funding, agreements, and new product launches, which help them improve their sales, increase their geographic reach, and improve their capacities to cater to a greater than existing customer base. A few strategic initiatives taken by key players operating in the gastrointestinal drugs market are mentioned below

In September 2023, Vivante Health closed US$ 31 million in a Series B funding round led by Mercato Partners, a new investor, to advance the digital digestive health platform. The new funding is mainly received due to the latest GIThrive platform enhancements that highlight the platform's unique ability to provide proper care at the right time. Series B Capital provides continued technological advancements designed to predict the onset and progression of gastrointestinal conditions and provide complete virtual care.

In May 2024, Strides Pharma Global Pte. Ltd received approval from the US FDA to market the generic version of Sucralfate Oral Suspension, 1gm/10 mL. The medication is used for the treatment of gastrointestinal diseases such as stomach ulcers, GERD, and stomach inflammation, as well as to help avoid stress ulcers.

In May 2023, AbbVie received US FDA approval for RINVOQ (upadacitinib) to treat adults with mild to severe active Crohn's disease having an inadequate response or intolerance to one or more TNF blockers. It is the seventh FDA approval for RINVOQ across rheumatology, dermatology, and gastroenterology, where it is now indicated in both ulcerative colitis and Crohn's disease.

Therefore, strategic initiatives by various companies focusing on the development of drugs for the treatment of digestive diseases are likely to offer growth opportunities to the gastrointestinal drugs market in the coming years.

Gastrointestinal Drugs Market: Competitive Landscape and Key Developments

Sanofi SA, GSK Plc, Johnson & Johnson, Bausch Health Companies Inc, AstraZeneca Plc, Takeda Pharmaceutical Co Ltd, AbbVie Inc, Bayer AG, Celltrion Inc, and Pfizer Inc are among the key companies operating in the gastrointestinal drugs market.

The US Food and Drug Administration, International Foundation for Gastrointestinal Disorders, and American college of gastroenterology, and The International Union of Basic and Clinical Pharmacology (IUPHAR) are among the primary and secondary sources referred to while preparing the gastrointestinal drugs market report.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. Gastrointestinal Drugs Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. Gastrointestinal Drugs Market - Key Market Dynamics

  • 5.1 Gastrointestinal Drugs Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Rising Cases of Gastrointestinal Diseases
    • 5.2.2 Increasing Development of Biologics
  • 5.3 Market Restraints
    • 5.3.1 High Cost of Biologics
    • 5.3.2 Average Cost of Biologic Drugs for Severe Ulcerative Colitis or Crohn's Disease
  • 5.4 Market Opportunities
    • 5.4.1 Strategic Initiatives by Companies
  • 5.5 Future Trends
    • 5.5.1 Increasing Research Investment for Novel Drug Development and Artificial Intelligence-Based Techniques
  • 5.6 Impact of Drivers and Restraints:

6. Gastrointestinal Drugs Market - Global Market Analysis

  • 6.1 Gastrointestinal Drugs Market Revenue (US$ Million), 2021-2031
  • 6.2 Gastrointestinal Drugs Market Forecast Analysis

7. Gastrointestinal Drugs Market Analysis - by Drug Class

  • 7.1 Biologics
    • 7.1.1 Overview
    • 7.1.2 Biologics: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Antidiarrheal and Laxatives
    • 7.2.1 Overview
    • 7.2.2 Antidiarrheal and Laxatives: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Acid Neutralizers
    • 7.3.1 Overview
    • 7.3.2 Acid Neutralizers: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.4 Anti-inflammatory Drugs
    • 7.4.1 Overview
    • 7.4.2 Anti-inflammatory Drugs: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.5 Antiemetic and Antinauseants
    • 7.5.1 Overview
    • 7.5.2 Antiemetic and Antinauseants: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.6 Others
    • 7.6.1 Overview
    • 7.6.2 Others: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

8. Gastrointestinal Drugs Market Analysis - by Application

  • 8.1 Irritable Bowel Syndrome
    • 8.1.1 Overview
    • 8.1.2 Irritable Bowel Syndrome: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Inflammatory Ulcerative Colitis
    • 8.2.1 Overview
    • 8.2.2 Inflammatory Ulcerative Colitis: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Crohns Disease
    • 8.3.1 Overview
    • 8.3.2 Crohns Disease: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.4 Gastroenteritis
    • 8.4.1 Overview
    • 8.4.2 Gastroenteritis: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.5 Celiac Disease
    • 8.5.1 Overview
    • 8.5.2 Celiac Disease: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.6 Others
    • 8.6.1 Overview
    • 8.6.2 Others: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

9. Gastrointestinal Drugs Market Analysis - by Route Of Administration

  • 9.1 Oral
    • 9.1.1 Overview
    • 9.1.2 Oral: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 Parenteral
    • 9.2.1 Overview
    • 9.2.2 Parenteral: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

10. Gastrointestinal Drugs Market Analysis - by Distribution Channel

  • 10.1 Hospital Pharmacies
    • 10.1.1 Overview
    • 10.1.2 Hospital Pharmacies: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.2 Retail Pharmacies
    • 10.2.1 Overview
    • 10.2.2 Retail Pharmacies: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.3 Online Pharmacies
    • 10.3.1 Overview
    • 10.3.2 Online Pharmacies: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

11. Gastrointestinal Drugs Market - Geographical Analysis

  • 11.1 North America
    • 11.1.1 North America Gastrointestinal Drugs Market Overview
    • 11.1.2 North America: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.1.2.1 North America: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Drug Class
      • 11.1.2.2 North America: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Application
      • 11.1.2.3 North America: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
      • 11.1.2.4 North America: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
    • 11.1.3 North America: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Country
      • 11.1.3.1 United States: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.3.1.1 United States: Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 11.1.3.1.2 United States: Gastrointestinal Drugs Market Breakdown, by Application
        • 11.1.3.1.3 United States: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 11.1.3.1.4 United States: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
      • 11.1.3.2 Canada: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.3.2.1 Canada: Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 11.1.3.2.2 Canada: Gastrointestinal Drugs Market Breakdown, by Application
        • 11.1.3.2.3 Canada: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 11.1.3.2.4 Canada: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
      • 11.1.3.3 Mexico: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.3.3.1 Mexico: Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 11.1.3.3.2 Mexico: Gastrointestinal Drugs Market Breakdown, by Application
        • 11.1.3.3.3 Mexico: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 11.1.3.3.4 Mexico: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
  • 11.2 Europe
    • 11.2.1 Europe Gastrointestinal Drugs Market Overview
    • 11.2.2 Europe: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.2.2.1 Europe: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Drug Class
      • 11.2.2.2 Europe: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Application
      • 11.2.2.3 Europe: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
      • 11.2.2.4 Europe: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
    • 11.2.3 Europe: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Country
      • 11.2.3.1 Germany: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.3.1.1 Germany: Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 11.2.3.1.2 Germany: Gastrointestinal Drugs Market Breakdown, by Application
        • 11.2.3.1.3 Germany: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 11.2.3.1.4 Germany: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
      • 11.2.3.2 United Kingdom: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.3.2.1 United Kingdom: Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 11.2.3.2.2 United Kingdom: Gastrointestinal Drugs Market Breakdown, by Application
        • 11.2.3.2.3 United Kingdom: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 11.2.3.2.4 United Kingdom: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
      • 11.2.3.3 France: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.3.3.1 France: Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 11.2.3.3.2 France: Gastrointestinal Drugs Market Breakdown, by Application
        • 11.2.3.3.3 France: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 11.2.3.3.4 France: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
      • 11.2.3.4 Italy: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.3.4.1 Italy: Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 11.2.3.4.2 Italy: Gastrointestinal Drugs Market Breakdown, by Application
        • 11.2.3.4.3 Italy: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 11.2.3.4.4 Italy: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
      • 11.2.3.5 Spain: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.3.5.1 Spain: Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 11.2.3.5.2 Spain: Gastrointestinal Drugs Market Breakdown, by Application
        • 11.2.3.5.3 Spain: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 11.2.3.5.4 Spain: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
      • 11.2.3.6 Rest of Europe: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.3.6.1 Rest of Europe: Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 11.2.3.6.2 Rest of Europe: Gastrointestinal Drugs Market Breakdown, by Application
        • 11.2.3.6.3 Rest of Europe: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 11.2.3.6.4 Rest of Europe: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
  • 11.3 Asia Pacific
    • 11.3.1 Asia Pacific Gastrointestinal Drugs Market Overview
    • 11.3.2 Asia Pacific: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.3.2.1 Asia Pacific: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Drug Class
      • 11.3.2.2 Asia Pacific: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Application
      • 11.3.2.3 Asia Pacific: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
      • 11.3.2.4 Asia Pacific: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
    • 11.3.3 Asia Pacific: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Country
      • 11.3.3.1 China: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.1.1 China: Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 11.3.3.1.2 China: Gastrointestinal Drugs Market Breakdown, by Application
        • 11.3.3.1.3 China: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 11.3.3.1.4 China: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
      • 11.3.3.2 Japan: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.2.1 Japan: Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 11.3.3.2.2 Japan: Gastrointestinal Drugs Market Breakdown, by Application
        • 11.3.3.2.3 Japan: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 11.3.3.2.4 Japan: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
      • 11.3.3.3 India: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.3.1 India: Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 11.3.3.3.2 India: Gastrointestinal Drugs Market Breakdown, by Application
        • 11.3.3.3.3 India: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 11.3.3.3.4 India: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
      • 11.3.3.4 Australia: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.4.1 Australia: Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 11.3.3.4.2 Australia: Gastrointestinal Drugs Market Breakdown, by Application
        • 11.3.3.4.3 Australia: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 11.3.3.4.4 Australia: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
      • 11.3.3.5 South Korea: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.5.1 South Korea: Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 11.3.3.5.2 South Korea: Gastrointestinal Drugs Market Breakdown, by Application
        • 11.3.3.5.3 South Korea: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 11.3.3.5.4 South Korea: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
      • 11.3.3.6 Rest of APAC: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.6.1 Rest of APAC: Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 11.3.3.6.2 Rest of APAC: Gastrointestinal Drugs Market Breakdown, by Application
        • 11.3.3.6.3 Rest of APAC: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 11.3.3.6.4 Rest of APAC: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
  • 11.4 Middle East & Africa
    • 11.4.1 Middle East & Africa Gastrointestinal Drugs Market Overview
    • 11.4.2 Middle East & Africa: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.4.2.1 Middle East & Africa: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Drug Class
      • 11.4.2.2 Middle East & Africa: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Application
      • 11.4.2.3 Middle East & Africa: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
      • 11.4.2.4 Middle East & Africa: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
    • 11.4.3 Middle East & Africa: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Country
      • 11.4.3.1 Saudi Arabia: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.3.1.1 Saudi Arabia: Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 11.4.3.1.2 Saudi Arabia: Gastrointestinal Drugs Market Breakdown, by Application
        • 11.4.3.1.3 Saudi Arabia: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 11.4.3.1.4 Saudi Arabia: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
      • 11.4.3.2 South Africa: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.3.2.1 South Africa: Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 11.4.3.2.2 South Africa: Gastrointestinal Drugs Market Breakdown, by Application
        • 11.4.3.2.3 South Africa: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 11.4.3.2.4 South Africa: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
      • 11.4.3.3 United Arab Emirates: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.3.3.1 United Arab Emirates: Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 11.4.3.3.2 United Arab Emirates: Gastrointestinal Drugs Market Breakdown, by Application
        • 11.4.3.3.3 United Arab Emirates: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 11.4.3.3.4 United Arab Emirates: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
      • 11.4.3.4 Rest of Middle East & Africa: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.3.4.1 Rest of Middle East & Africa: Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 11.4.3.4.2 Rest of Middle East & Africa: Gastrointestinal Drugs Market Breakdown, by Application
        • 11.4.3.4.3 Rest of Middle East & Africa: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 11.4.3.4.4 Rest of Middle East & Africa: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
  • 11.5 South & Central America
    • 11.5.1 South & Central America Gastrointestinal Drugs Market Overview
    • 11.5.2 South & Central America: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.5.2.1 South & Central America: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Drug Class
      • 11.5.2.2 South & Central America: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Application
      • 11.5.2.3 South & Central America: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
      • 11.5.2.4 South & Central America: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
    • 11.5.3 South & Central America: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Country
      • 11.5.3.1 Brazil: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.3.1.1 Brazil: Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 11.5.3.1.2 Brazil: Gastrointestinal Drugs Market Breakdown, by Application
        • 11.5.3.1.3 Brazil: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 11.5.3.1.4 Brazil: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
      • 11.5.3.2 Argentina: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.3.2.1 Argentina: Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 11.5.3.2.2 Argentina: Gastrointestinal Drugs Market Breakdown, by Application
        • 11.5.3.2.3 Argentina: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 11.5.3.2.4 Argentina: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
      • 11.5.3.3 Rest of South & Central America: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.3.3.1 Rest of South & Central America: Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 11.5.3.3.2 Rest of South & Central America: Gastrointestinal Drugs Market Breakdown, by Application
        • 11.5.3.3.3 Rest of South & Central America: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 11.5.3.3.4 Rest of South & Central America: Gastrointestinal Drugs Market Breakdown, by Distribution Channel

12. Industry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies in Gastrointestinal Drugs Market
  • 12.3 Organic Growth Strategies
    • 12.3.1 Overview
  • 12.4 Inorganic Growth Strategies
    • 12.4.1 Overview

13. Company Profiles

  • 13.1 Sanofi SA
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 GSK Plc
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 Johnson & Johnson
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 Bausch Health Companies Inc
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 AstraZeneca Plc
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 Takeda Pharmaceutical Co Ltd
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 AbbVie Inc
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 Bayer AG
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 Celltrion Inc
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 Pfizer Inc
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments

14. Appendix

  • 14.1 About The Insight Partners
  • 14.2 Glossary of Terms